Christine Winterholler, Maria Helena Coura, Pedro Montoya
{"title":"无创脑电刺激治疗纤维肌痛综合征的临床、神经生理和神经化学效应——系统综述和荟萃分析","authors":"Christine Winterholler, Maria Helena Coura, Pedro Montoya","doi":"10.3389/fpain.2025.1593746","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fibromyalgia syndrome (FMS) is linked to central sensitization and neuroplastic alterations that contribute to chronic pain, fatigue, cognitive, sleep, and affective disturbances. Conventional treatments offer limited benefit. Non-invasive transcranial electrical stimulation (tES), particularly transcranial direct current stimulation (tDCS), may modulate brain function and relieve symptoms, but findings remain inconsistent.</p><p><strong>Objective: </strong>To systematically review and meta-analyze the effects of tES on clinical, neurophysiological, neuropsychological, and neurochemical outcomes in FMS.</p><p><strong>Methods: </strong>Seven databases were searched for studies published between April 2013 and April 2023. Eligible designs included randomized controlled trials, cross-over, one-arm, and case studies involving adult FMS patients. Data extraction followed Cochrane Collaboration guidelines and used RevMan 6.6.0.</p><p><strong>Results: </strong>Anodal tDCS produced short- to mid-term reductions in pain and mood symptoms, especially when applied over M1 or DLPFC. Longer interventions and repeated sessions enhanced effects, though protocol heterogeneity limited comparability. Both subjective (VAS, NRS) and objective (QST) measures confirmed pain reduction. Cognitive improvements were inconsistent, and quality of life effects were limited. Neurophysiological and neurochemical changes suggested possible mechanisms, though findings varied. Study quality was mixed, with small sample sizes and methodological inconsistencies. Meta-analysis revealed statistically significant but small effects on pain (Hedges' <i>g</i> < 0.2), with limited evidence on clinical relevance.</p><p><strong>Conclusions: </strong>Anodal tDCS may offer short-term relief of pain and mood symptoms in FMS, potentially through modulation of cortical excitability and neuroplasticity. However, due to variability in findings and methodological limitations, its clinical relevance remains unclear. Future trials should use standardized protocols, assess long-term effects, and include clinically meaningful outcome measures.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD42023412332, PROSPERO CRD42023412332.</p>","PeriodicalId":73097,"journal":{"name":"Frontiers in pain research (Lausanne, Switzerland)","volume":"6 ","pages":"1593746"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354543/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical, neurophysiological and neurochemical effects of non-invasive electrical brain stimulation in fibromyalgia syndrome-a systematic review and meta-analysis.\",\"authors\":\"Christine Winterholler, Maria Helena Coura, Pedro Montoya\",\"doi\":\"10.3389/fpain.2025.1593746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Fibromyalgia syndrome (FMS) is linked to central sensitization and neuroplastic alterations that contribute to chronic pain, fatigue, cognitive, sleep, and affective disturbances. Conventional treatments offer limited benefit. Non-invasive transcranial electrical stimulation (tES), particularly transcranial direct current stimulation (tDCS), may modulate brain function and relieve symptoms, but findings remain inconsistent.</p><p><strong>Objective: </strong>To systematically review and meta-analyze the effects of tES on clinical, neurophysiological, neuropsychological, and neurochemical outcomes in FMS.</p><p><strong>Methods: </strong>Seven databases were searched for studies published between April 2013 and April 2023. Eligible designs included randomized controlled trials, cross-over, one-arm, and case studies involving adult FMS patients. Data extraction followed Cochrane Collaboration guidelines and used RevMan 6.6.0.</p><p><strong>Results: </strong>Anodal tDCS produced short- to mid-term reductions in pain and mood symptoms, especially when applied over M1 or DLPFC. Longer interventions and repeated sessions enhanced effects, though protocol heterogeneity limited comparability. Both subjective (VAS, NRS) and objective (QST) measures confirmed pain reduction. Cognitive improvements were inconsistent, and quality of life effects were limited. Neurophysiological and neurochemical changes suggested possible mechanisms, though findings varied. Study quality was mixed, with small sample sizes and methodological inconsistencies. Meta-analysis revealed statistically significant but small effects on pain (Hedges' <i>g</i> < 0.2), with limited evidence on clinical relevance.</p><p><strong>Conclusions: </strong>Anodal tDCS may offer short-term relief of pain and mood symptoms in FMS, potentially through modulation of cortical excitability and neuroplasticity. However, due to variability in findings and methodological limitations, its clinical relevance remains unclear. Future trials should use standardized protocols, assess long-term effects, and include clinically meaningful outcome measures.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD42023412332, PROSPERO CRD42023412332.</p>\",\"PeriodicalId\":73097,\"journal\":{\"name\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"volume\":\"6 \",\"pages\":\"1593746\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354543/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fpain.2025.1593746\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in pain research (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fpain.2025.1593746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Clinical, neurophysiological and neurochemical effects of non-invasive electrical brain stimulation in fibromyalgia syndrome-a systematic review and meta-analysis.
Background: Fibromyalgia syndrome (FMS) is linked to central sensitization and neuroplastic alterations that contribute to chronic pain, fatigue, cognitive, sleep, and affective disturbances. Conventional treatments offer limited benefit. Non-invasive transcranial electrical stimulation (tES), particularly transcranial direct current stimulation (tDCS), may modulate brain function and relieve symptoms, but findings remain inconsistent.
Objective: To systematically review and meta-analyze the effects of tES on clinical, neurophysiological, neuropsychological, and neurochemical outcomes in FMS.
Methods: Seven databases were searched for studies published between April 2013 and April 2023. Eligible designs included randomized controlled trials, cross-over, one-arm, and case studies involving adult FMS patients. Data extraction followed Cochrane Collaboration guidelines and used RevMan 6.6.0.
Results: Anodal tDCS produced short- to mid-term reductions in pain and mood symptoms, especially when applied over M1 or DLPFC. Longer interventions and repeated sessions enhanced effects, though protocol heterogeneity limited comparability. Both subjective (VAS, NRS) and objective (QST) measures confirmed pain reduction. Cognitive improvements were inconsistent, and quality of life effects were limited. Neurophysiological and neurochemical changes suggested possible mechanisms, though findings varied. Study quality was mixed, with small sample sizes and methodological inconsistencies. Meta-analysis revealed statistically significant but small effects on pain (Hedges' g < 0.2), with limited evidence on clinical relevance.
Conclusions: Anodal tDCS may offer short-term relief of pain and mood symptoms in FMS, potentially through modulation of cortical excitability and neuroplasticity. However, due to variability in findings and methodological limitations, its clinical relevance remains unclear. Future trials should use standardized protocols, assess long-term effects, and include clinically meaningful outcome measures.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
